The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Nonalcoholic Fatty Liver Disease: Focus on Lipoprotein and Lipid Deregulation
Open accessAbstract
Obesity with associated comorbidities is currently a worldwide epidemic and among the most challenging health conditions in the 21st century. A major metabolic consequence of obesity is insulin resistance which underlies the pathogenesis of the metabolic syndrome. Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of obesity and metabolic syndrome. It comprises a disease spectrum ranging from simple steatosis (fatty liver), through nonalcoholic steatohepatitis (NASH) to fibrosis, and ultimately liver cirrhosis. Abnormality in lipid and lipoprotein metabolism accompanied by chronic inflammation is the central pathway for the development of metabolic syndrome-related diseases, such as atherosclerosis, cardiovascular disease (CVD), and NAFLD. This paper focuses on pathogenic aspect of lipid and lipoprotein metabolism in NAFLD and the relevant mouse models of this complex multifactorial disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581 · cited 1×
“It strongly associates with obesity, insulin resistance, hypertension, and dyslipidaemia and is now regarded as the liver manifestation of metabolic syndrome [6].”
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
Protection from obesity-induced insulin resistance in mice lacking TNF-α function
Uysal, K. T., Wiesbrock, S. M., Marino, M. W., & Hotamisligil, G. S. (1997) · Nature · doi:10.1038/39335 · Cited by 2,234
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772
Goldstein, J. L., & Brown, M. S. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.179564 · Cited by 1,344
Janssen, I., Katzmarzyk, P. T., Boyce, W. F., Vereecken, C., Mulvihill, C., Roberts, C., Currie, C., Pickett, W., & The Health Behaviour in School‐Aged Children Obesity Working Group (2005) · Obesity Reviews · doi:10.1111/j.1467-789x.2005.00176.x · Cited by 1,169 · cited 1×
“The prevalence of childhood obesity has significantly increased over the past three decades [3, 4] and boosted the prevalence of NAFLD in adolescents (reviewed in [5]).”
From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus
Musunuru, K., Strong, A., Frank-Kamenetsky, M., Lee, N. E., Ahfeldt, T., Sachs, K. V., Li, X., Li, H., Kuperwasser, N., Ruda, V. M., et al. (2010) · Nature · doi:10.1038/nature09266 · Cited by 1,140
Cited by
Molecular pathways of nonalcoholic fatty liver disease development and progression
Bessone, F., Razori, M. V., & Roma, M. G. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2947-0 · Cited by 610
De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose
Sanders, F. W. B., & Griffin, J. L. (2016) · Biological Reviews · doi:10.1111/brv.12178 · Cited by 539
Kim, Y.-R., Lee, E.-J., Shin, K.-O., Kim, M. H., Pewzner-Jung, Y., Lee, Y.-M., Park, J.-W., Futerman, A. H., & Park, W.-J. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0340-1 · Cited by 474
How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?
Geng, Y., Faber, K. N., de Meijer, V. E., Blokzijl, H., & Moshage, H. (2021) · Hepatology International · doi:10.1007/s12072-020-10121-2 · Cited by 432
Recent insights on the role of cholesterol in non-alcoholic fatty liver disease
Arguello, G., Balboa, E., Arrese, M., & Zanlungo, S. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.05.015 · Cited by 306
Distinctly altered gut microbiota in the progression of liver disease
Xie, G., Wang, X., Liu, P., Wei, R., Chen, W., Rajani, C., Hernandez, B. Y., Alegado, R., Dong, B., Li, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8466 · Cited by 219
“These findings suggest a link between the gut microbiota-derived endotoxin and the pathogenesis of NAFLD, thereby evidencing a key role for the gut microbiota as an orchestrator of the gut-liver axis.”
BackgroundInfluentialSvendsen, P., Graversen, J. H., Etzerodt, A., Hager, H., Røge, R., Grønbæk, H., Christensen, E. I., Møller, H. J., Vilstrup, H., & Moestrup, S. K. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.11.004 · Cited by 84
Implications of Sortilin in Lipid Metabolism and Lipid Disorder Diseases
Gao, A., Cayabyab, F. S., Chen, X., Yang, J., Wang, L., Peng, T., & Lv, Y. (2017) · DNA and Cell Biology · doi:10.1089/dna.2017.3853 · Cited by 43
Sharma, N., Singh, L., Sharma, A., Kumar, A., & Mahajan, D. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107375 · Cited by 16
Jin, L., Cui, Y., Zhang, Q., Xiong, Y., Zheng, X., Ye, J., Zhang, A., Xiao, Z., Zhuang, Z., Liang, G., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114053 · Cited by 1
Metadata
- Authors
- Fon Tacer, K., & Rozman, D.
- Venue
- Journal of Lipids
- Publisher
- Hindawi Limited
- Published
- 2011
- Volume
- 2011
- Pages
- 1-14
- ISSN
- 2090-3030 (ISSN-L)
- 2090-3049
- OpenAlex
- W2135095267
- Cited by
- 231
- References
- 24
- FWCI
- 9.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.